Earnings call transcript: American Shared Hospital Srvcs misses Q2 2025 forecasts

American Shared Hospital Services (AMS) reported a Q2 2025 net loss of $0.04 per share, significantly missing analyst expectations for a $0.04 gain, despite achieving a 16% sequential revenue increase to $7.1 million. This earnings miss, partly due to declining equipment leasing revenue and higher operational costs, resulted in a 2.59% stock decline. While AMS is strategically expanding its direct patient services and international footprint, particularly in Mexico, the mixed results underscore near-term profitability challenges against a backdrop of long-term growth initiatives.

Analysis

American Shared Hospital Services (AMS) presented a mixed financial picture for Q2 2025, defined by a significant earnings miss counterbalanced by sequential revenue growth and a strategic pivot. The company reported a net loss per share of $0.04, starkly contrasting with analyst forecasts of a $0.04 profit and triggering a 2.59% decline in its stock price. This bottom-line weakness stems from the underperformance and contract expirations in its legacy Equipment Leasing segment, where revenue fell to $3.6 million from $3.9 million year-over-year. Concurrently, the company's strategic shift toward direct patient services is gaining traction, with that segment's revenue growing 12% YoY to $3.5 million, driving an overall 16% sequential increase in total revenue to $7.1 million. Despite the top-line momentum, profitability is challenged by higher operational costs and the inherently lower gross margin profile of the new direct care business, reflected in a YoY decline in adjusted EBITDA from $2.0 million to $1.7 million. Management's outlook remains optimistic, predicated on long-term growth from its international expansion in Mexico and operational ramp-up in its Rhode Island centers, which are now fully staffed, positioning the company as a 'show-me' story for investors.

Key Decisions for Investors

• Investors should weigh the significant Q2 earnings miss and declining legacy business against the management's long-term growth strategy centered on direct patient care and international expansion.
• Closely monitor treatment volume growth in the newly staffed Rhode Island centers and the new Mexico facility in subsequent quarters, as these are the primary catalysts for validating the company's strategic pivot and returning to profitability.
• Given the stock's 19.51% year-to-date decline and reported undervaluation, consider the current price as a potential entry point for long-term, risk-tolerant investors who believe management can successfully execute its growth initiatives and overcome near-term margin pressures.